Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Efficacy of short-course versus standard-course blinatumomab in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia

Liu Ge, Yile Zhou, Yinjun Lou, Hao Ai, Liping Mao, Qian Wang, Hongfei Wu, Hongyan Tong, Xudong Wei, Jie Jin, Huafeng Wang, Qingsong Yin

Blood (2025) 146 (Supplement 1): 1562.

https://doi.org/10.1182/blood-2025-1562

Published: 2025

Journal Articles

Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study

Jin Zhou, Qian Wang, Tao You, Yun Wang, Depei Wu, Haiwen Huang

Blood (2025) 146 (Supplement 1): 7267.

https://doi.org/10.1182/blood-2025-7267

Published: 2025

Journal Articles

Mendelian randomization reveals the causative role of genetically predicted viral infection in pan-lymphoma risk

Wanying Chen, Jin Zhou, Qian Wang, Yun Wang, Depei Wu, Tao You, Haiwen Huang

Blood (2025) 146 (Supplement 1): 5449.

https://doi.org/10.1182/blood-2025-5449

Published: 2025

Journal Articles

Targeting METTL3 disrupts oncogenic transcriptional programs and activates immune and apoptotic pathways in Acute Myeloid Leukemia

Harshita Ravi, Qian Wang

Blood (2025) 146 (Supplement 1): 6764.

https://doi.org/10.1182/blood-2025-6764

Published: 2025

Journal Articles

Golidocitinib-based therapy in relapsed/refractory mycosis fungoides and Sézary syndrome: A real-world retrospective analysis

Qian Wang, Shu Wang, QinYuan zhu, Ziqi liu, ShangLin Jin, Qiong Huang, TianLing Ding, Tong Chen

Blood (2025) 146 (Supplement 1): 8079.

https://doi.org/10.1182/blood-2025-8079

Published: 2025

Journal Articles

Short-term blinatumomab regimen in newly diagnosed induction and MRD-negative consolidation treatment of B-cell acute lymphoblastic leukemia

Yile Zhou, Liu Ge, Liping Mao, Yinjun Lou, Hao Ai, Qian Wang, Hongyan Tong, Jie Jin, Qingsong Yin, Huafeng Wang

Blood (2025) 146 (Supplement 1): 3336.

https://doi.org/10.1182/blood-2025-3336

Published: 2025

Journal Articles

KIT mutant/core binding factor (CBF)-negative (CBF-Neg) AML might be an underestimated and distinct subgroup with poor prognosis: A single-center retrospective study

Rui Jiang, Zhibo Zhang, Yizi Liu, Wenqiang Qu, Zhao Zeng, Linlin Wang, Qian Wang, Jia Yin, Depei Wu, Suning Chen

Blood (2025) 146 (Supplement 1): 7003.

https://doi.org/10.1182/blood-2025-7003

Published: 2025

Journal Articles

Mitoxantrone hydrochloride liposome-based CMOP±R regimen achieves superior response in treatment-Naïve non-Hodgkin lymphoma: A phase III clinical trial with matching-adjusted indirect comparison

Tao You, Jin Zhou, Yun Wang, Chenwen Wang, Qian Wang, Xiao Ma, Peng Xu, Yuhu Feng, Jun Fang, Miao Zheng, Depei Wu, Haiwen Huang

Blood (2025) 146 (Supplement 1): 1924.

https://doi.org/10.1182/blood-2025-1924

Published: 2025

Journal Articles

Efficacy and safety of the polatuzumab, acalabrutinib, rituximab, and lenalidomide (Pola-AR2) regimen as first-line therapy in unfit or frail patients with diffuse large B-cell lymphoma

Qian Wang, Jin Zhou, Yun Wang, Tao You, Depei Wu, Haiwen Huang

Blood (2025) 146 (Supplement 1): 3742.

https://doi.org/10.1182/blood-2025-3742

Published: 2025

Journal Articles

Real-world efficacy and safety of pomalidomide-rituximab-based combination therapy in newly diagnosed extranodal diffuse large B-cell lymphoma

Qingsong Yin, Hongfei Wu, Hao Ai, Qian Wang, Liu Ge

Blood (2025) 146 (Supplement 1): 7220.

https://doi.org/10.1182/blood-2025-7220

Published: 2025

Journal Articles

The single-center retrospective analysis of steroid-free rmap regimen (ruxolitinib, montelukast, azithromycin, and pirfenidone) treating moderate-to-severe bronchiolitis obliterans syndrome (BOS).

Xi Yang, chenglong Li, Hong Zheng, qian Wang, hang Zhang, Xiaobing Huang

Blood (2025) 146 (Supplement 1): 2507.

https://doi.org/10.1182/blood-2025-2507

Published: 2025

Journal Articles

Lncrna malnc modulates ATRA-induced transcriptional reprogramming in acute promyelocytic leukemia cells

Qian Wang, Kuan-Ying Yu

Blood (2025) 146 (Supplement 1): 6798.

https://doi.org/10.1182/blood-2025-6798

Published: 2025

Journal Articles

Targeting B-cell lymphoma surface protein with a novel peptide: Therapeutic potential and clinical implications

Qian Cheng, Ying Shen, Dandan Lin, Qian Wang, Haiwen Huang, Depei Wu

Blood (2025) 146 (Supplement 1): 2550.

https://doi.org/10.1182/blood-2025-2550

Published: 2025

Journal Articles

Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study

Blood (2024) 144 (Supplement 1): 2187.

https://doi.org/10.1182/blood-2024-206919

Published: 2024

Journal Articles

Single-Cell RNA-Sequencing Identifies TCF1 and BCL11B Upregulation As Predictors of Blinatumomab Efficacy in B-Cell Acute Lymphoblastic Leukemia Patients

Qingsong Yin, Taotao Liang, Shan Wang, Yuqing Chen, Wenli Zuo, Qinglan Zhang, Hongxia Ma, Hao Ai, Qian Wang, Hongfei Wu

Blood (2024) 144 (Supplement 1): 2822.

https://doi.org/10.1182/blood-2024-203038

Published: 2024

Journal Articles

A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 498.

https://doi.org/10.1182/blood-2024-193738

Published: 2024

Journal Articles

Preliminary Investigation of the Efficacy and Safety of Zanubrutinib in Combination with R-Chemo As First-Line Therapy Inpatients with Newly Diagnosed Mantle Cell Lymphoma

Qian Wang, Sicheng Ai, Tao You, Depei Wu, Haiwen Huang

Blood (2024) 144 (Supplement 1): 6296.

https://doi.org/10.1182/blood-2024-204476

Published: 2024

Journal Articles

Upregulation of BCL11B and TCF1 in CD8+ T Cells Indicates the Reconstitution of T Cell Immunity in CLL Patients Treated with Ibrutinib

Qingsong Yin, Taotao Liang, Shan Wang, Hao Ai, Qian Wang, Hongfei Wu

Blood (2024) 144 (Supplement 1): 6766.

https://doi.org/10.1182/blood-2024-198322

Published: 2024

Journal Articles

Screening for Hearing Loss in Hematologic Cancer Survivors

Ese-Onosen Omoijuanfo, Keri Plevniak, Alex Eishingdrelo, Jaime A Perez, James Martin, Qian Wang, Melinda Hsu

Blood (2024) 144 (Supplement 1): 7584.

https://doi.org/10.1182/blood-2024-204050

Published: 2024

Journal Articles

Helical Tomotherapy and Melphalan As the Conditioning Regimen in Autologous Stem Cell Transplantation for Multiple Myeloma with Extramedullary Plasmacytoma: A Single Center Clinical Research

Pan Liu, Qian Wang, Fuling Zhou

Blood (2023) 142 (Supplement 1): 7075.

https://doi.org/10.1182/blood-2023-188275

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Efficacy of short-course versus standard-course blinatumomab in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia

Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study

Mendelian randomization reveals the causative role of genetically predicted viral infection in pan-lymphoma risk

Targeting METTL3 disrupts oncogenic transcriptional programs and activates immune and apoptotic pathways in Acute Myeloid Leukemia

Golidocitinib-based therapy in relapsed/refractory mycosis fungoides and Sézary syndrome: A real-world retrospective analysis

Short-term blinatumomab regimen in newly diagnosed induction and MRD-negative consolidation treatment of B-cell acute lymphoblastic leukemia

KIT mutant/core binding factor (CBF)-negative (CBF-Neg) AML might be an underestimated and distinct subgroup with poor prognosis: A single-center retrospective study

Mitoxantrone hydrochloride liposome-based CMOP±R regimen achieves superior response in treatment-Naïve non-Hodgkin lymphoma: A phase III clinical trial with matching-adjusted indirect comparison

Efficacy and safety of the polatuzumab, acalabrutinib, rituximab, and lenalidomide (Pola-AR2) regimen as first-line therapy in unfit or frail patients with diffuse large B-cell lymphoma

Real-world efficacy and safety of pomalidomide-rituximab-based combination therapy in newly diagnosed extranodal diffuse large B-cell lymphoma

The single-center retrospective analysis of steroid-free rmap regimen (ruxolitinib, montelukast, azithromycin, and pirfenidone) treating moderate-to-severe bronchiolitis obliterans syndrome (BOS).

Lncrna malnc modulates ATRA-induced transcriptional reprogramming in acute promyelocytic leukemia cells

Targeting B-cell lymphoma surface protein with a novel peptide: Therapeutic potential and clinical implications

Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study

Single-Cell RNA-Sequencing Identifies TCF1 and BCL11B Upregulation As Predictors of Blinatumomab Efficacy in B-Cell Acute Lymphoblastic Leukemia Patients

A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma

Preliminary Investigation of the Efficacy and Safety of Zanubrutinib in Combination with R-Chemo As First-Line Therapy Inpatients with Newly Diagnosed Mantle Cell Lymphoma

Upregulation of BCL11B and TCF1 in CD8+ T Cells Indicates the Reconstitution of T Cell Immunity in CLL Patients Treated with Ibrutinib

Screening for Hearing Loss in Hematologic Cancer Survivors

Helical Tomotherapy and Melphalan As the Conditioning Regimen in Autologous Stem Cell Transplantation for Multiple Myeloma with Extramedullary Plasmacytoma: A Single Center Clinical Research

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only